NCT07406633 2026-04-17
KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting
Kumquat Biosciences Inc.
Phase 2 Recruiting
Clinical Trials
32 trialsNCT01742299 2026-04-01
Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator
Novartis
Phase 4 Active not recruiting
NCT05381753 2026-02-11
Safety and Efficacy of Avapritinib in Chinese Patients With Gastrointestinal Stromal Tumor (GIST) in the Real World
CStone Pharmaceuticals
Completed
NCT06655246 2026-02-05
A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
Kura Oncology, Inc.
Phase 1 Recruiting
NCT05245968 2026-01-20
A Study of Pimitespib in Combination With Imatinib in Patients With GIST (CHAPTER-GIST-101)
Taiho Pharmaceutical Co., Ltd.
Phase 1 Active not recruiting
NCT01294202 2024-08-02
A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST
Astex Pharmaceuticals, Inc.
Phase 2 Completed
NCT00812240 2023-02-01
Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST)
AB Science
Phase 3 Terminated
NCT01275222 2021-06-25
Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors
Novartis
Phase 1/2 Completed
NCT01468688 2020-12-21
A Dose-finding Study of a Combination of Imatinib and BKM120 in the Treatment of 3rd Line GIST Patients
Novartis
Phase 1 Completed
NCT00135005 2020-12-08
Study of AMN107 With Imatinib in Gastrointestinal Stromal Tumors (GIST)
Novartis
Phase 1 Completed
NCT00510354 2020-09-10
Radix
Novartis
Phase 4 Completed
NCT00867113 2018-03-14
Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST)
Novartis
Phase 2 Completed
NCT00455559 2018-02-22
Ph II Study of Perifosine Plus Gleevec for Patients With GIST
AEterna Zentaris
Phase 2 Completed
NCT01172548 2017-05-31
INV555
Novartis
Phase 2 Completed
NCT00150072 2017-02-23
Efficacy and Safety of Imatinib in Chordoma
Novartis
Phase 2 Completed
NCT00171912 2017-02-23
Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes
Novartis
Phase 2 Completed
NCT00154388 2016-11-18
Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases
Novartis
Phase 2 Completed
NCT01483014 2016-11-18
CONVERT
Novartis
Phase 2 Completed
NCT00785785 2016-06-16
ENESTg1
Novartis
Phase 3 Completed
NCT01613053 2015-04-24
MACS2226
Novartis
No longer available
NCT01751919 2014-10-01
A Clinical Trial to Compare the Pharmacokinetics of Imatinib Mesylate Tablet 400mg (1 Tablet) and Glivec Film-coated Tablet 100mg (4 Tablets)(Phase I)
Dong-A ST Co., Ltd.
Phase 1 Completed
NCT00237185 2014-08-19
A Study of the Efficacy and Safety of Imatinib Mesylate in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing C-kit Gene
Novartis
Phase 2 Completed
NCT02103322 2014-06-27
Comparative Bioequivalence Study in Adult Patients Suffering From Chronic Myeloid Leukemia & Gastrointestinal Stromal Tumor Under Fed Conditions
Amneal Pharmaceuticals, LLC
Phase 2/3 Completed
NCT00751036 2014-03-26
MACS0375
Novartis
Phase 3 Terminated
NCT00441155 2013-05-13
Patients Completing Core Protocol (CAMN107A2103), Exhibiting Stable Disease (SD), Partial Response (PR) or Complete Response (CR) to Nilotinib in Combination With Imatinib
Novartis
Phase 1 Completed
NCT01270984 2012-10-31
Imatinib
Chong Kun Dang Pharmaceutical
Phase 1 Completed
NCT00171977 2012-08-07
Post-Marketing Clinical Study of Postoperative Adjuvant Therapy With Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors (GIST)
Novartis
Phase 4 Completed
NCT00427583 2012-08-07
Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors
Novartis
Phase 2/3 Terminated
NCT00471328 2012-06-12
ENEST
Novartis
Phase 3 Completed
NCT00237172 2012-05-01
Phase II Clinical Study of Imatinib Mesylate in Patients With Malignant Gastrointestinal Stromal Tumors (Extension Study)
Novartis
Phase 2 Completed
NCT00940563 2011-07-01
A Prospective, Multicenter Study on Best Clinical Use of Imatinib in the Advanced Gastrointestinal Stromal Tumors
Novartis
Phase 2 Completed
NCT00372567 2011-03-17
Safety And Effectiveness Of Daily Dosing With Sunitinib Or Imatinib In Patients With Gastrointestinal Stromal Tumors
Pfizer
Phase 3 Terminated